IL281343A - Methods for treating pancreatitis - Google Patents

Methods for treating pancreatitis

Info

Publication number
IL281343A
IL281343A IL281343A IL28134321A IL281343A IL 281343 A IL281343 A IL 281343A IL 281343 A IL281343 A IL 281343A IL 28134321 A IL28134321 A IL 28134321A IL 281343 A IL281343 A IL 281343A
Authority
IL
Israel
Prior art keywords
methods
treating pancreatitis
pancreatitis
treating
Prior art date
Application number
IL281343A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Publication of IL281343A publication Critical patent/IL281343A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL281343A 2018-09-10 2021-03-09 Methods for treating pancreatitis IL281343A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862729354P 2018-09-10 2018-09-10
PCT/US2019/050262 WO2020055768A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis

Publications (1)

Publication Number Publication Date
IL281343A true IL281343A (en) 2021-04-29

Family

ID=69776851

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281343A IL281343A (en) 2018-09-10 2021-03-09 Methods for treating pancreatitis

Country Status (13)

Country Link
US (1) US12378320B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849605A4 (cg-RX-API-DMAC7.html)
JP (1) JP7560445B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210073515A (cg-RX-API-DMAC7.html)
CN (2) CN113056286B (cg-RX-API-DMAC7.html)
AU (1) AU2019337564A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004444A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112382A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021000585A1 (cg-RX-API-DMAC7.html)
IL (1) IL281343A (cg-RX-API-DMAC7.html)
MX (1) MX2021002761A (cg-RX-API-DMAC7.html)
SG (1) SG11202102416SA (cg-RX-API-DMAC7.html)
WO (1) WO2020055768A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020055768A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis
US20250297027A1 (en) * 2021-01-12 2025-09-25 Yeda Research And Development Co. Ltd. Antibodies to cancer glycosylation and uses thereof
CA3214598A1 (en) * 2021-03-26 2022-09-29 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
US12661076B2 (en) * 2024-03-26 2026-06-23 Hepatiq, Inc. Determining pancreas disease using functional imaging

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4471057A (en) * 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JPS63159763A (ja) * 1986-12-24 1988-07-02 Fujirebio Inc 逆受身凝集反応試薬
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
FI20070853A0 (fi) 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2010017500A2 (en) 2008-08-08 2010-02-11 Immunomedics, Inc. Anti-pancreatic cancer antibodies
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CN105517561A (zh) 2013-07-17 2016-04-20 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CN105764526B (zh) 2013-08-26 2020-12-15 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2020055768A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis

Also Published As

Publication number Publication date
JP7560445B2 (ja) 2024-10-02
CN113056286B (zh) 2025-04-29
EP3849605A1 (en) 2021-07-21
AU2019337564A1 (en) 2021-05-06
CA3112382A1 (en) 2020-03-19
CL2021000585A1 (es) 2021-08-13
WO2020055768A1 (en) 2020-03-19
BR112021004444A2 (pt) 2021-06-01
JP2022500382A (ja) 2022-01-04
EP3849605A4 (en) 2022-06-15
CL2022000091A1 (es) 2022-11-18
CN120267815A (zh) 2025-07-08
KR20210073515A (ko) 2021-06-18
US20220049011A1 (en) 2022-02-17
US12378320B2 (en) 2025-08-05
MX2021002761A (es) 2021-05-31
SG11202102416SA (en) 2021-04-29
CN113056286A (zh) 2021-06-29

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
EP3703607C0 (en) AUTOMATIC TREATMENT PLANNING
IL261935A (en) Methods of treatment of cholestatic diseases
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
IL257252A (en) Methods of treating fgf21-associated disorders
IL291687A (en) Methods for treating myelofibrosis and related conditions
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
IL256056A (en) Ezh2 inhibitors for treating lymphoma
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
IL256025A (en) Methods of diagnosing and treating cancer
DK3778595T3 (da) Pancreatitisbehandling
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
IL269174A (en) Methods for treating complement-mediated diseases and disorders
DK3442972T3 (da) Bromdomænehæmmere
EP3564335A4 (en) SURFACE TREATMENT AGENT
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
IL261047A (en) Taf1 inhibitors for the therapy of cancer
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
PT3265087T (pt) Método de tratamento com tradipitant
PL3393468T3 (pl) Metody leczenia niedoboru odporności
IL272092A (en) Methods of treating behavior alterations
DK3294769T3 (da) Behandling for multipelt myelom (mm)
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
IL282041A (en) Egfr inhibitors for treating keratodermas
EP3532063A4 (en) POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION